Supplements
What Supplements Actually Do to TMAO Levels
TMAO — trimethylamine N-oxide — is a gut-derived metabolite linked to atherosclerosis, kidney disease, and elevated cardiovascular risk, yet most people have never heard of it. Emerging research shows that certain supplements can meaningfully shift TMAO metabolism, but the evidence is more nuanced than the headlines suggest. Here's what the science actually says.

What Is TMAO and Why Does It Matter?
Trimethylamine N-oxide (TMAO) is produced when gut bacteria metabolize choline, lecithin, and L-carnitine from food — particularly red meat, eggs, and certain fish. The liver converts the intermediate trimethylamine (TMA) into TMAO via flavin-containing monooxygenase 3 (FMO3) enzymes. What leaves your liver enters systemic circulation and, at elevated concentrations, appears to accelerate atherosclerotic plaque formation, promote platelet hyper-reactivity, and impair reverse cholesterol transport.
A landmark study by Tang et al. (2013) in The New England Journal of Medicine found that plasma TMAO levels independently predicted major adverse cardiovascular events (MACE) in a cohort of 4,007 patients undergoing elective cardiac evaluation (PMID: 23614584). Elevated TMAO was associated with a 2.5-fold increased risk of MACE after adjusting for traditional risk factors. This put TMAO squarely on the cardiovascular biomarker map.
Beyond the heart, research has linked elevated TMAO to chronic kidney disease progression (Missailidis et al., Nutrients 2021; PMID: 34444760) and insulin resistance. Because TMAO originates largely in the gut, it sits at the intersection of diet, microbiome composition, and metabolic health — which is exactly why supplementation strategies are being actively explored.
---
How Supplements Can Influence TMAO
There are three main mechanisms by which supplements may modulate TMAO levels:
- Inhibiting TMA lyase activity in gut bacteria that cleave choline and carnitine.
- Shifting the microbiome toward species that produce less TMA.
- Supporting hepatic FMO3 enzyme regulation to reduce conversion of TMA to TMAO.
No single supplement attacks all three pathways simultaneously, which is why understanding each category matters.
---
Resveratrol and Polyphenols
Resveratrol, a polyphenol found in grapes and berries, has received attention as a potential TMAO modulator. A randomized crossover trial by Annadora et al. and later work from Chen et al. (mBio 2016; PMID: 27094330) showed that resveratrol supplementation in mice significantly reduced plasma TMAO by altering bile acid metabolism and suppressing hepatic FMO3 expression. While direct human RCT data on resveratrol and TMAO specifically remain limited, the mechanistic pathway is well-characterized.
Broader polyphenol-rich extracts — including those from grape seed, pomegranate, and green tea (EGCG) — appear to reshape gut microbiota composition, reducing populations of Prevotella copri and other TMA producers. This microbiome-modifying effect is thought to explain part of the cardiovascular benefit attributed to Mediterranean-style diets.
---
Omega-3 Fatty Acids
Omega-3 supplementation (EPA and DHA) has shown consistent effects on cardiovascular biomarkers, and emerging evidence suggests it may also influence TMAO. A 2021 meta-analysis of omega-3 trials noted favorable modulation of gut microbial diversity, including increases in Lactobacillus and Bifidobacterium species that are not major TMA producers (Costantini et al., Nutrients 2021). Meanwhile, research on supplements that affect triglycerides consistently shows omega-3s reducing TG levels by 15–30% at clinical doses of 2–4 g/day EPA+DHA.
For TMAO specifically, omega-3s likely work indirectly — by modifying the substrate availability and microbial environment rather than directly blocking TMA synthesis. This is an important distinction: omega-3s are unlikely to dramatically slash a high TMAO reading on their own, but they are a cornerstone of the cardiovascular support picture.
---
Probiotics and Gut Flora Support
Because TMAO originates in the gut, probiotic supplementation is a logical intervention. Specific strains matter enormously here. Lactobacillus plantarum and certain Bifidobacterium strains have been studied for their ability to compete with TMA-producing bacteria without themselves generating significant TMA.
A 2022 randomized trial in overweight adults found that a multi-strain probiotic supplement over 12 weeks significantly reduced fasting plasma TMAO compared to placebo, alongside improvements in gut microbiome diversity (Li et al., Frontiers in Nutrition 2022; PMID: 35958549). The effect size was modest (approximately 18% reduction), but statistically meaningful and accompanied by reductions in inflammatory markers.
This connects directly to cardiovascular biomarker conversations — if you are tracking metrics like LDL particle number or homocysteine, understanding how gut health influences these downstream markers gives a more complete metabolic picture.
---
Allicin (Garlic Extract) and TMAO Inhibition
One of the most mechanistically direct supplements studied for TMAO is allicin, the bioactive compound in garlic. Wang et al. (Journal of Agricultural and Food Chemistry 2015) demonstrated that allicin can inhibit microbial TMA lyase enzymes — the precise step where choline and carnitine are cleaved into TMA before liver conversion. This is significant because it targets the source, not a downstream consequence.
Doses used in experimental settings range from 400–1,200 mg standardized garlic extract daily. Aged garlic extract (AGE) has also shown favorable effects on cardiovascular endpoints including blood pressure and arterial stiffness, suggesting multiple parallel mechanisms may be at work. For anyone already investigating their total cholesterol supplement options, garlic extract is worth placing on the radar as a compound with both lipid-modifying and TMAO-relevant properties.
---
Berberine
Berberine is an alkaloid extracted from plants like Berberis vulgaris and has been studied extensively for metabolic support. Its relevance to TMAO is primarily through microbiome remodeling: berberine shifts the gut microbial community toward species with lower TMA-producing capacity while also improving short-chain fatty acid production.
A 2020 clinical trial found that berberine (500 mg twice daily for 12 weeks) significantly altered gut flora composition in patients with metabolic syndrome, with downstream reductions in circulating TMA-related metabolites (Cui et al., Phytomedicine 2020). Berberine also has well-documented effects on blood glucose and lipid panels, making it a genuinely multi-target compound rather than a TMAO-specific agent.
It's worth noting that berberine can interact with medications, particularly those metabolized by CYP3A4 enzymes, and anyone on prescription drugs should discuss supplementation with their healthcare provider before starting.
---
3,3-Dimethyl-1-Butanol (DMB) — A Research Chemical, Not a Supplement
DMB made headlines after a 2015 Cell paper by Wang et al. showed it inhibited TMA lyase and reduced TMAO in mice, suppressing atherosclerosis development. It's important to be clear: DMB is a research compound found in trace amounts in balsamic vinegar and cold-pressed olive oil, not a commercially available supplement. Including it here because it appears frequently in TMAO supplement discussions — but no peer-reviewed human trial has used it in supplement form. The finding is scientifically meaningful as a proof of concept for microbiome-targeted therapy, but it is not something available to purchase.
---
What Does NOT Work as Advertised
Several popular supplements are frequently marketed in connection with TMAO without compelling evidence:
- L-carnitine supplements: Because L-carnitine is itself a TMAO precursor in people with certain microbiome compositions, supplementation can paradoxically increase TMAO in meat eaters while having minimal effect in vegans (Koeth et al., Nature Medicine 2013; PMID: 23563705). This is a critical nuance — L-carnitine for cardiovascular or exercise performance is not automatically harmful, but it is not a TMAO reducer.
- Generic probiotic blends: Strain selection matters. Broad-spectrum probiotics not specifically studied for TMA suppression may not move the needle on TMAO at all.
- Choline supplements: Supplemental choline can serve as a substrate for TMA production in susceptible individuals. This doesn't mean choline is universally bad — brain and liver health benefits are well-established — but it's context-dependent.
---
How Ones Addresses This
TMAO is not a single-supplement problem. It lives at the intersection of gut health, hepatic enzyme activity, cardiovascular biomarker risk, and dietary pattern — which is exactly why a personalized approach is more effective than a one-size-fits-all stack.
Ones uses AI-driven analysis of blood work, wearable data, and health history to build custom capsule formulas calibrated to your actual biomarker profile. For individuals with elevated TMAO or related cardiovascular risk markers, several ingredients in the Ones catalog are directly relevant:
- Omega-3 (EPA/DHA): Included at clinical doses to support lipid metabolism and gut microbial diversity, addressing the indirect TMAO pathway through microbiome composition.
- Heart Support System Blend: Ones' proprietary Heart Support blend is formulated for cardiovascular biomarker optimization and pairs well with TMAO-related risk reduction strategies.
- Liver Support System Blend: Given that FMO3 enzyme activity in the liver is the final conversion step for TMA to TMAO, Ones' Liver Support blend targets hepatic function — a mechanistically relevant angle that most standard cardiovascular stacks ignore entirely.
The formula is built in 6 or 9-capsule daily plans, calibrated by the AI based on your findings, so the capsule budget is never wasted on ingredients that don't match your specific lab picture.
---
A Note on Testing TMAO
TMAO is not on a standard lipid panel. It requires a specialty cardiovascular biomarker test — available through some preventive cardiology labs and emerging direct-to-consumer panels. If you're already monitoring metrics like homocysteine or Lp(a), adding TMAO testing gives a more complete picture of non-traditional cardiovascular risk. Talk with your healthcare provider about whether TMAO testing is appropriate for your situation.
---
Key Takeaways
- TMAO is a gut-derived metabolite linked to cardiovascular, renal, and metabolic risk — elevated levels independently predict adverse cardiac events.
- Probiotics with specific strains (L. plantarum, Bifidobacterium) show the most direct evidence for reducing plasma TMAO, with modest but statistically significant effects in RCTs.
- Allicin (garlic extract) may inhibit TMA lyase at the microbial level — one of the most mechanistically direct supplement interventions available.
- Berberine modulates the gut microbiome composition and has multi-target metabolic benefits, including downstream effects on TMAO-related metabolites.
- Omega-3s support cardiovascular and microbial health indirectly but are unlikely to be a primary TMAO intervention on their own.
- L-carnitine can increase TMAO in certain individuals — a nuance frequently overlooked in supplement marketing.
- Personalized approaches that account for your actual lab data, microbiome context, and cardiovascular risk markers — like those built by Ones — are better positioned to address TMAO holistically than any generic stack.